{"id":4070,"date":"2026-11-04T09:00:00","date_gmt":"2026-11-04T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4070"},"modified":"2026-11-04T21:49:29","modified_gmt":"2026-11-05T01:49:29","slug":"oral-azacitidine-matches-injection-exposure-in-mds-study","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4070","title":{"rendered":"Oral Azacitidine Matches Injection Exposure in MDS Study"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Taiho Oncology; Taiho Pharmaceutical<\/p>\n

Event Type<\/strong><\/p>\n

Detailed Phase 3 pharmacokinetic data<\/p>\n

Modality<\/strong><\/p>\n

Small molecule (oral hypomethylating agent)<\/p>\n

Asset<\/strong><\/p>\n

ASTX030 (azacitidine plus cedazuridine)<\/p>\n

Target<\/strong><\/p>\n

DNA methyltransferase; cytidine deaminase<\/p>\n

Disease Area<\/strong><\/p>\n

MDS and CMML<\/p>\n

Summary<\/h4>\n

Taiho reported detailed AZTOUND data on November 4 after a September topline announcement. In 83 patients in a randomized crossover Phase 3 pharmacokinetic analysis, oral azacitidine plus cedazuridine produced a total-cycle exposure ratio of 95.2% versus subcutaneous azacitidine (90% CI 86.5\u2013104.7). This is exposure equivalence, not a demonstrated clinical outcome advantage.<\/p>\n

The Phase 3 primary PK endpoint was met. The company reported similar LINE-1 demethylation profiles. In 71 patients in the safety analysis, 68% had grade 3 or higher treatment-emergent adverse events and 34% had serious adverse events. A separate pooled Phase 1\/2 MDS group of 45 had a 44.4% overall response rate and 20% complete response; that uncontrolled earlier-stage cohort should not be read as a head-to-head Phase 3 efficacy result. An NDA is planned, not filed.<\/p>\n

Deep Analysis<\/h4>\n

Interpretation A:<\/strong> systemic exposure equivalence may support an oral substitute for repeated injections if regulators accept the bridge and CMC controls. The crossover design and tight PK confidence interval support this. Counterargument: identical AUC does not ensure identical concentration-time effects, adherence, long-term tolerability, or clinical outcomes.<\/p>\n

Interpretation B:<\/strong> convenience could be offset by dosing complexity or exposure variability across body-surface-area groups. Body-surface-area dosing is disclosed and supports the need for subgroup review, while similar demethylation offers some pharmacodynamic reassurance. The next evidence is complete peak\/trough and variability analysis, phase 3 clinical activity, adherence, comparative cytopenias and infections, and FDA review of the bridge.<\/p>\n

Company and Product Background<\/h4>\n

Taiho\u2019s ASTX030 combines azacitidine, a DNA hypomethylating agent used in MDS and CMML, with cedazuridine, an inhibitor of cytidine deaminase intended to preserve oral azacitidine exposure. MDS and CMML are clonal myeloid marrow disorders with anemia, cytopenias and leukemic progression risk.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • The new signal is detailed numeric PK and safety disclosure; the primary endpoint success itself was announced September 30.<\/li>\n
  • This avoids counting the older event as new.<\/li>\n
  • The December ASH presentation remains a future venue.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The exposure bridge is credible but is narrower than an efficacy claim. Regulatory portability depends on whether PK and pharmacodynamic similarity adequately support the proposed MDS and CMML label.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 3 of 5. Signal Direction: positive for PK endpoint, uncertain for comparative clinical benefit. Confidence in Facts: moderate-high for detailed sponsor data; full study report unavailable. Confidence in Interpretation: moderate for exposure bridging, low for patient outcomes.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Taiho reported detailed AZTOUND data on November 4 after a September topline announcement. In 83 patients in a randomized crossover Phase 3 pharmacokinetic analysis, oral azacitidine plus cedazuridine produced a total-cycle exposure ratio of…<\/p>\n","protected":false},"author":1,"featured_media":4074,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1370,1369,1368],"class_list":["post-4070","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-myelodysplastic-syndromes","tag-oral-azacitidine","tag-taiho-oncology"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4070"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4070\/revisions"}],"predecessor-version":[{"id":4088,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4070\/revisions\/4088"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4074"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}